earnings
confidence high
sentiment positive
materiality 0.75
Surmodics Q3 revenue $29.6M, GAAP loss narrows; raises FY2025 guidance
SURMODICS INC
2025-Q3 EPS reported
-$0.99
revenue$87,574,000
- Revenue $29.6M (-3% YoY); GAAP net loss $5.3M ($0.37/sh) vs loss $7.6M ($0.53) prior year.
- Non-GAAP net income $0.8M ($0.06/sh) vs non-GAAP loss $3.9M ($0.27); Adjusted EBITDA $3.4M vs $1.6M.
- FY2025 guidance raised: revenue $116.5-118.5M (prev $114-117M); non-GAAP net loss/sh $(0.35)-(0.20) vs prior $(0.62)-(0.42).
- Medical Device revenue -5% to $22.2M; IVD +6% to $7.4M; Pounce Thrombectomy sales +35% YoY.
- Merger with GTCR ($43/sh) pending FTC litigation; preliminary injunction hearing scheduled Aug 21, 2025.
item 2.02item 9.01